As he announces the solutions that will be on display at Pharmintech, for the first time in Italy, MG2's Director of Strategic Innovation Sergio Cicognani focuses on the company's unique vision, which combines technological innovation, ability to respond to an increasingly challenging market, and targeted sales strategies.

The time- honoured company, which has been based in Pianoro, since the 1960s, has long been renowned as a leading manufacturer of encapsulation machines and a pioneer in pharmaceutical packaging. Today, it is in the midst of a strategic revolution that is transforming its organisation, which began with the products and is now projected towards new sales trajectories. Sergio Cicognani, Director of Strategic Innovation at MG2, talked with us about it.

How important is exhibiting at Pharmintech for you?

 “MG2 has been exhibiting at Pharmintech since the very first show, because we see the event as a platform for dialogue with the market and an opportunity to showcase our range to the international audience, which includes end users, trade professionals, and buyers attending the fair. We therefore expect great things in terms of the potential for networking it has always shown. That is why we will be offering an absolute preview for Italy  in Milan this year (Hall 2, Stand B60), unveiling the two encapsulation machines from our new E series, Essentia and Electa, which feature a production capacity of 200,000 capsules/hour.”

What technology solutions and in particular innovations are you working on at this time?

 “The new E series is definitely one of these. It is one particular solution that is experiencing significant success due to a variety of factors. The first is the HCD (human-centred design) approach, which has revolutionised the design of MG2 encapsulation machines, generating considerable interest in the market. The second is the refreshment of our communication materials for  sales and marketing, which has boosted sales of both new solutions and existing products already in the catalogue.

In recent times, we have experienced growing interest in encapsulation, which has broadened market horizons for us.

That is why in 2025 we will be expanding our range of metering units, which can be progressively retrofitted  into existing machines according to evolving production needs  thanks to the modularity of our designs. Changeovers from units for powder to units for liquids, tablets,  and micro-tablets will be quick and easy.

Further development is also planned for the E series, with a new model due to be introduced during the year to enhance the range.”

Industry trends and future: what way is the market heading?

 “Artificial intelligence is driving innovation in all areas, and pharmaceuticals is no exception. Its main contribution will be increased availability of new molecules,  leading to expanding treatment possibilities. More advanced data analysis will also make it possible to reduce drug development times, speeding up their entry in the market.

For MG2, this scenario poses both challenges and opportunities. We will have to interpret the new needs, adapt to an ever faster pace, and manage growing production complexity, strengthening our position as innovators in the field.”